Go Un-Pro
Sunday Science: Testosterone Therapy – Risks, Benefits & Longevity Debate Summary by Speaker Dr. Brent Laartz Discusses testosterone decline with age (0.4-2.6%/year, 30-50% by 50-60), low T ( Reviews studies: - Low T associated with 1.5-2.3x higher all-cause, CV, cancer mortality (2010 European Heart Journal cohort; 2011 JCEM meta-analysis). - Frailty mediates 35% of low T mortality risk. - Eunuch/castration studies (Korea, Poland, animals): 10-20% longer lifespan, but pre-puberty vs. late-life low T. - TRT studies: Decreased mortality if levels normalized (2012, 2015 European Heart Journal cohorts); short-term (3 years) benefit; non-normalized TRT no benefit. Notes biases in cohorts (healthy user effect); no RCTs yet. Emphasizes N=1 individualized approach considering personal risks (e.g., prostate/heart disease). Key Points and Decisions **Low Endogenous Testosterone**: Strongly linked to higher mortality (all-cause, CV, cancer); associated with frailty, metabolic issues. **Castration/Eunuch Data**: Suggests lifelong low T may extend life, but not directly comparable to adult TRT. **TRT Evidence**: Cohort studies show mortality reduction with normalized levels (esp. long-term), but short-term CV risks possible; no definitive RCTs. **No Firm Decisions**: Informational only; no endorsements for/against TRT; highlights need for RCTs to resolve controversy. Next Steps **Research**: Await randomized controlled trials (RCTs) for definitive TRT mortality data. **Individuals**: Check testosterone/health markers regularly (yearly+); consult physicians for personalized risks/benefits; prioritize resistance training, healthy lifestyle. **Audience**: Seek professional medical advice; follow show on YouTube, Spotify, Apple Podcasts, social media, goonpro.com.
15 afleveringen
Reacties
0Wees de eerste die een reactie plaatst
Meld je nu aan en word lid van de Go Un-Pro community!